CELC Key Statistics, Chart & Performance
The current stock price of CELC is 101.14 USD. In the past month the price increased by 3.73%. In the past year, price increased by 630.78%.
CELC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.12 | 402.80B | ||
| AMGN | AMGEN INC | 15.15 | 178.45B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.52 | 116.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.32 | 81.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 799.47 | 53.87B | ||
| INSM | INSMED INC | N/A | 37.48B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.44 | 25.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 22.12B | ||
| INCY | INCYTE CORP | 15.69 | 19.77B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About CELC
Company Profile
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Company Info
CELCUITY INC
16305 36th Ave N Ste 100
Minneapolis MINNESOTA 55446 US
CEO: Brian F. Sullivan
Employees: 87
Phone: 17633920767
CELCUITY INC / CELC FAQ
What does CELCUITY INC do?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
What is the current price of CELC stock?
The current stock price of CELC is 101.14 USD. The price decreased by -0.02% in the last trading session.
What is the dividend status of CELCUITY INC?
CELC does not pay a dividend.
What is the ChartMill rating of CELCUITY INC stock?
CELC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CELC stock?
16 analysts have analysed CELC and the average price target is 112.71 USD. This implies a price increase of 11.44% is expected in the next year compared to the current price of 101.14.
What is the market capitalization of CELC stock?
CELCUITY INC (CELC) has a market capitalization of 4.68B USD. This makes CELC a Mid Cap stock.
Can you provide the upcoming earnings date for CELCUITY INC?
CELCUITY INC (CELC) will report earnings on 2026-03-30, after the market close.
CELC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CELC. When comparing the yearly performance of all stocks, CELC is one of the better performing stocks in the market, outperforming 99.67% of all stocks.
CELC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CELC. The financial health of CELC is average, but there are quite some concerns on its profitability.
CELC Financial Highlights
Over the last trailing twelve months CELC reported a non-GAAP Earnings per Share(EPS) of -3.67. The EPS decreased by -40.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.19% | ||
| ROE | -139.12% | ||
| Debt/Equity | 2.74 |
CELC Forecast & Estimates
16 analysts have analysed CELC and the average price target is 112.71 USD. This implies a price increase of 11.44% is expected in the next year compared to the current price of 101.14.